Literature DB >> 1352208

Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin.

U Christians1, M Sattler, H M Schiebel, C Kruse, H H Radeke, A Linck, K F Sewing.   

Abstract

Rapamycin was incubated with human liver microsomes and an NADPH regenerating system, the metabolites were purified by semipreparative HPLC, and their structures were elucidated by direct chemical ionization and FAB-MS. At least six fractions were isolated containing rapamycin metabolites, indicating that rapamycin is metabolized by the human liver cytochrome P-450 system. One of these metabolites was identified as 41-O-demethyl-rapamycin. A second metabolite was hydroxylated in a yet unknown position. These two metabolites retained immunosuppressive activity in a phytohemagglutinin-stimulated human lymphocyte assay with IC50S of 1 and 1.5 nmol/liter, respectively. Rapamycin was metabolized by rat small intestinal microsomes to at least two metabolites, indicating extra-hepatic metabolism of rapamycin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352208

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

Review 1.  Clinical pharmacokinetics of sirolimus.

Authors:  K Mahalati; B D Kahan
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Tacrolimus (FK 506) biotransformation in primary rat hepatocytes depends on extracellular matrix geometry.

Authors:  A Bader; E Knop; K H Böker; O Crome; N Frühauf; A K Gonschior; U Christians; H Esselmann; R Pichlmayr; K F Sewing
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-03       Impact factor: 3.000

3.  Sirolimus reduces polycystic liver volume in ADPKD patients.

Authors:  Qi Qian; Hui Du; Bernard F King; Sumedha Kumar; Patrick G Dean; Fernando G Cosio; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 10.121

4.  Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber.

Authors:  A Lampen; U Christians; A K Gonschior; A Bader; I Hackbarth; W von Engelhardt; K F Sewing
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

5.  Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs.

Authors:  Hui Hong; Emmanuelle Coutanceau; Marion Leclerc; Laxmee Caleechurn; Peter F Leadlay; Caroline Demangel
Journal:  PLoS Negl Trop Dis       Date:  2008-10-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.